Kestra Private Wealth Services LLC Grows Stock Holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Kestra Private Wealth Services LLC increased its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 9.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 4,140 shares of the medical equipment provider’s stock after buying an additional 373 shares during the quarter. Kestra Private Wealth Services LLC’s holdings in Intuitive Surgical were worth $1,397,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Portside Wealth Group LLC lifted its position in Intuitive Surgical by 8.2% in the fourth quarter. Portside Wealth Group LLC now owns 816 shares of the medical equipment provider’s stock valued at $275,000 after purchasing an additional 62 shares during the period. Sequoia Financial Advisors LLC lifted its position in Intuitive Surgical by 58.0% in the fourth quarter. Sequoia Financial Advisors LLC now owns 8,315 shares of the medical equipment provider’s stock valued at $2,805,000 after purchasing an additional 3,054 shares during the period. Kades & Cheifetz LLC acquired a new stake in Intuitive Surgical in the fourth quarter valued at about $230,000. Blair William & Co. IL lifted its position in Intuitive Surgical by 3.1% in the third quarter. Blair William & Co. IL now owns 377,371 shares of the medical equipment provider’s stock valued at $110,302,000 after purchasing an additional 11,400 shares during the period. Finally, Assenagon Asset Management S.A. lifted its position in Intuitive Surgical by 21.2% in the third quarter. Assenagon Asset Management S.A. now owns 739,471 shares of the medical equipment provider’s stock valued at $216,140,000 after purchasing an additional 129,194 shares during the period. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Intuitive Surgical Stock Up 1.0 %

Shares of NASDAQ ISRG opened at $381.36 on Friday. Intuitive Surgical, Inc. has a 52-week low of $254.85 and a 52-week high of $403.76. The firm has a fifty day moving average of $385.56 and a 200-day moving average of $348.56. The stock has a market capitalization of $135.27 billion, a PE ratio of 68.84, a P/E/G ratio of 4.88 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last announced its quarterly earnings data on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.40 by $0.10. Intuitive Surgical had a net margin of 27.16% and a return on equity of 12.91%. The company had revenue of $1.89 billion during the quarter, compared to analysts’ expectations of $1.87 billion. During the same period in the previous year, the company earned $1.00 EPS. The business’s quarterly revenue was up 11.5% compared to the same quarter last year. Equities research analysts expect that Intuitive Surgical, Inc. will post 4.8 EPS for the current fiscal year.

Insider Activity

In other news, SVP Mark Brosius sold 196 shares of the business’s stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $400.00, for a total transaction of $78,400.00. Following the completion of the sale, the senior vice president now directly owns 1,842 shares of the company’s stock, valued at approximately $736,800. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, Director Alan J. Levy sold 2,000 shares of the company’s stock in a transaction on Tuesday, April 23rd. The shares were sold at an average price of $370.70, for a total transaction of $741,400.00. Following the completion of the sale, the director now directly owns 25,319 shares of the company’s stock, valued at approximately $9,385,753.30. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Mark Brosius sold 196 shares of the company’s stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $400.00, for a total transaction of $78,400.00. Following the sale, the senior vice president now directly owns 1,842 shares of the company’s stock, valued at $736,800. The disclosure for this sale can be found here. Insiders sold 226,928 shares of company stock valued at $87,833,828 in the last ninety days. Company insiders own 0.90% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently issued reports on ISRG. Jefferies Financial Group lifted their price target on shares of Intuitive Surgical from $365.00 to $375.00 and gave the company a “hold” rating in a research report on Friday, April 19th. Royal Bank of Canada lifted their price target on shares of Intuitive Surgical from $400.00 to $432.00 and gave the company an “outperform” rating in a research report on Wednesday, January 24th. Piper Sandler lifted their price target on shares of Intuitive Surgical from $425.00 to $435.00 and gave the company an “overweight” rating in a research report on Friday, April 19th. Citigroup lifted their price objective on Intuitive Surgical from $428.00 to $462.00 and gave the stock a “buy” rating in a research report on Wednesday, April 3rd. Finally, StockNews.com downgraded Intuitive Surgical from a “buy” rating to a “hold” rating in a research report on Thursday, February 29th. Five investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, Intuitive Surgical has an average rating of “Moderate Buy” and a consensus target price of $396.17.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.